162271-10-5

Basic information

• Product Name: 2-BroMo-3-(MethoxyMethoxy)pyridine, 96%
• Synonyms: 2-BroMo-3-(MethoxyMethoxy)pyridine, 96%;2-BROMO-3-(METHOXYMETHOXY)PYRIDINE(WXC05973)
• CAS NO: 162271-10-5
• Molecular Formula: C₇H₈BrNO₂
• Molecular Weight: 218
• Mol File: 162271-10-5.mol
• Article Data: 9

Chemical Properties

• Melting Point: 35-37℃
• Boiling Point: 279.1±30.0 °C(Predicted)
• Appearance: /
• Density: 1.496±0.06 g/cm3(Predicted)
• PKA: -0.90±0.10(Predicted)
• CAS DataBase Reference: 2-BroMo-3-(MethoxyMethoxy)pyridine, 96%(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BroMo-3-(MethoxyMethoxy)pyridine, 96%(162271-10-5)
• EPA Substance Registry System: 2-BroMo-3-(MethoxyMethoxy)pyridine, 96%(162271-10-5)

Safety Data

• Hazardous Substances Data: 162271-10-5(Hazardous Substances Data)

Upstream product

• 6602-32-0 2-bromo-pyridin-3-ol 
• 107-30-2 chloromethyl methyl ether 
• 109-00-2 3-HYDROXYPYRIDINE 

Downstream Products

• 198710-41-7 2-(3-bromo-4-fluorobenzoyl)-3-methoxymethoxypyridine 
• 1589-82-8 phenylmagnesium bromide 

Relevant articles and documents

Efficient and fast Heck vinylation of 2-bromo-6-methyl pyridines with methylacrylate. Application to the synthesis of 6-methyl cyclopenta[b]pyridinone

Heck vinylation of 2-bromo-6-methyl-3-substituted pyridines using η3-allylpalladium chloride dimer/P(o-Tol)3 complex/toluene and dimethylacetamide (DMA) as co-solvent with methyl acrylate is reported. Electronic and steric effects were investigated engaging diversely 2-bromo-3,6-disubstituted pyridines. As application, a new synthesis of the 6-methyl cyclopenta[b]pyridinone building-block connecting Heck vinylation, alkene reduction and Dieckmann condensation is described.

INHIBITORS OF THE KYNURENINE PATHWAY

The present application provides novel inhibitors of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase, metabolites thereof, and phannaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. A therapeutically effective amount of one or more of the compounds of formula (I) is useful in treating diseases resulting from dysregulation of the kynurenine pathway. Compounds of formula (I) act by inhibiting the enzymatic activity or expression of indoleamine 2,3-dioxygenase-1 and/or indoleamine 2,3-dioxygenase-2 and/or tryptophan 2,3-dioxygenase.

MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME

The present invention provides novel conformationally-defined macrocyclic compounds that can function as selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, bone disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.